Roman516, thx, I love your evaluation of the device and its current development status and I have faith in your experience with it. I understand and agree with the end result and believe the submission is near. I know the genius is in the Flaskworks design. I am a firm believer in accountability and in their organization I am not sure who has been ultimately responsible for their product development but as long as it is all properly done all is now good.
Roman516, thx, I love your evaluation of the device and its current development status and I have faith in your experience with it. I understand and agree with the end result and believe the submission is near. I know the genius is in the Flaskworks design. I am a firm believer in accountability and in their organization I am not sure who has been ultimately responsible for their product development but as long as it is all properly done all is now good.
Roman - The market has yet to realize the added value of EDEN in the valuation conversation. Effectively, we have two standalone businesses under the same offering. DNDN was the first Dendritic Cell based treatment approved, and we know that manufacturing caused it's demise. I can't think of a better performance than LP's execution and forethought to get manufacturing capability to this point. It's absolutely remarkable!! The nature of the undertaking coupled with the nature of developing biotech can cause people to lose sight of the marvel that's taking place before them.
Market Data 
Markets 
AI
